PFIZER INC.

The mRNA Therapeutics Market was valued at USD 11.82 billion in 2023 and is projected to reach USD 48.65 billion by 2032, with a CAGR of 17.04%. The market's growth is driven by mRNA-based vaccines against COVID-19, advancements in mRNA-based cancer therapies, and regulatory approvals. North America leads the market, followed by Europe, while Asia Pacific is expected to grow the fastest.

SciTech Development adds John Chapman, CPA, to its Strategic Advisory Board as Senior Financial Advisor, leveraging his expertise in financial strategy and the pharmaceutical sector to guide the company's growth. Chapman, formerly a Senior Partner at KPMG, will support SciTech's lead drug, ST-001 nanoFenretinide, currently in Phase 1 clinical trials for T-Cell Non-Hodgkin Lymphoma.

Tel Aviv University researchers developed a COVID-19 vaccine that can be stored at room temperature and administered as a nasal spray, breaking Pfizer and Moderna's duopoly. The nanovaccine, composed of 200-nanometer particles, trains the immune system against all common variants and doesn't require cold storage, making it ideal for developing countries.

The toxoplasmosis treatment drugs market is projected to grow from $3.16 billion in 2023 to $4.18 billion by 2028, driven by rising prevalence, product innovations, and increased healthcare expenditure.

The Global Biomarkers market is projected to grow from USD 81.04 billion in 2023 to USD 221.78 billion by 2032, at a CAGR of 13.4%. Key players include Siemens Healthcare, Johnson & Johnson, Pfizer, and others. The market is segmented by types, applications, and geography, with North America dominating and Asia-Pacific showing the fastest growth. Market trends include AI integration, non-invasive biomarkers, and personalized medicine. Challenges include high costs, regulatory approvals, and ethical concerns.

Filgotinib, an oral JAK inhibitor, met only one of four primary endpoints in a phase III Crohn's disease trial, possibly due to study design issues. Clinical remission was achieved by more patients previously treated with biologics, but endoscopic response was not met. Maintenance phase showed better results, with clinical and endoscopic remission rates improving. Study limitations included early endoscopic assessment and high placebo response rates.

The Dame Barbara Windsor Dementia Goals programme, launched in 2022 with £95 million and later increased to £120 million, aims to accelerate dementia treatment development. Co-Chaired by Hilary Evans-Newton and Nadeem Sarwar, it includes initiatives like the Neurodegeneration Initiative and a Clinical Trials Delivery Accelerator. Key appointments include Scott Mitchell as People’s Champion and Ruth McKernan as Chair of the Scientific Advisory Board. Funding supports innovations in biomarkers and clinical trials, with additional £20 million announced in 2023 for the CTDA.

The FDA issues guidance on accelerated approvals, emphasizing sponsors must have confirmatory trials underway at approval. Labels will detail drug usefulness limitations. Accelerated approval should not be considered if adequate trials are impossible. Sponsors must conduct confirmatory trials diligently, with FDA review of protocols. FDA may withdraw approval for non-compliance, safety concerns, or misleading promotions. Examples include Pfizer's Oxbryta withdrawal and Sarepta's Elevidys market retention despite trial failure.

The GCC pharmaceutical market, led by Saudi Arabia, is rapidly expanding due to factors like population growth and lifestyle diseases. The market is expected to exceed US$ 12 Billion by 2030, with branded and imported drugs dominating. Clinical trials in the region involve over 250 drugs, and healthcare transformation programs are driving growth. Local manufacturing is increasing, especially in generics and biosimilars, while digital health innovations are enhancing market efficiency.

DelveInsight's report on the Obsessive Compulsive Disorder (OCD) market forecasts a significant CAGR growth from 2020-2034, driven by increasing prevalence and awareness, and the launch of multiple-stage pipeline products. The market was valued at approximately USD 1000 million in 2023, with 12,082,000 prevalent cases of OCD across 7MM in 2022, expected to rise by 2034. Key companies include Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, and others, with therapies such as Troriluzole, Fluvoxamine maleate, and BHV-4157. The report provides insights into epidemiology, market trends, and treatment scenarios in the US, EU4, and Japan.